Advertising Age - Prospecting for next goldmine; With fewer acquisition targets, Pfizer grapples with lack of new blockbusters.(Pfizer Report)
Byline: RICH THOMASELLI
Much has been made of Pfizer’s penchant for acquiring other pharmaceutical marketers with strong brands or potential blockbusters in the pipeline.
But as the opportunities for further pharma acquisitions or mergers begin to dwindle, Pfizer must now look to its own pipeline.
Especially now: The drug company is looking at a reduction of more than $5 billion in annual sales over the next year when Neurontin, Diflucan, Zithromax and Accupril come off patent protection. zovirax.
Most Popular
5 Regular Mistakes In Public Speaking
10 Jobs That Pay $30 An Hour
13 Job Interview Mistakes To Avoid
Public Speaking: 7 Secrets Of Great Public Speakers
3 Questions No Job Seeker Ever Wants To Be Asked?
Sluggish research and development has been an industrywide problem in recent years. …
Read the rest of this article with a Free Trial at HighBeam Research.
